Roche announces launch of Evrysdi® (risdiplam) for treatment of SMA patients in India

Roche Evrysdi

Evrysdi® was first approved by the US FDA in August 2020 and is today available in India within 11 months of the US approval. Roche today announced the launch of Evrysdi® (risdiplam), the first and only approved treatment in India for Spinal Muscular Atrophy (SMA) patients. Evrysdi® (risdiplam) is the first and only oral treatment … Read more